Latest Headlines

Latest Headlines

Next-gen infusion pump startup Ivenix nabs $42M to get to market

Infusion pumps are one of the more problematic categories of medical devices with myriad adverse events, including deaths, and recalls associated with the devices. Ivenix expects that its next-gen infusion management system could improve patient safety and workflow efficiency--as well as to adhere to more stringent FDA guidance on infusion systems issued in December.

NovoCure files for up to $300M IPO on strength of first-line glioblastoma device

NovoCure has filed for an IPO to raise up to $300 million on the strength of a potential FDA approval for its Optune device in combination with chemotherapy for patients with newly diagnosed glioblastoma.

CeQur reels in $100M for insulin infusion smart patch device

Swiss diabetes device maker CeQur roped in $100 million in a Series C round for its patchlike insulin infusion device, helping the company ramp up operations and launch its product next year.

Germany's coramaze receives $5M in Series A to develop transcatheter mitral valve repair device

Germany's coramaze technologies announced that it is receiving €4.5 million ($5.05 million) in a Series A round led by Israel's Elron Electronic Industries, making it the latest player in the burgeoning field of transcatheter mitral valve devices.

Shanghai Pharmaceutical raises funds for online-to-offline sales push with eye on ethical products

A key drug company in China fired a new salvo in the online over-the-counter healthcare market with an eye on wider sales of ethical products in hopes the China Food and Drug Administration (CFDA) will come through on plans to allow online sales of prescription drugs at some point this year.  

Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive

Private equity group Essex Woodlands has snapped up a 16% stake in surgical peripheral nerve solutions company AxoGen. The company raised $17.5 million to back its existing regenerative medicine products, as well as to develop new candidates for nerves severed during prostate cancer surgery and lower extremity nerve injuries. The financing is expected to put the company in the black for the first time.

Patterson shares fall on missed sales and earnings targets

Shares of Patterson Companies were down more than 7% to $45.53 on Thursday morning, after the distributor announced disappointing results for its fiscal first quarter. The company reported sales of $1.1 billion and earnings of $46.9 million, or $0.47 a share. Even though earnings were up more than 17% year-over-year, analysts had been expecting EPS of $0.54 on sales of $1.8 billion.

PE group to invest up to $28.4M in Israeli cardio, sleep apnea micro-cap Itamar

Israeli Viola Private Equity will invest up to $28.4 million in an Israeli publicly listed micro-cap medical device company Itamar Medical. The investment will make the firm the largest shareholder in the cardiovascular and sleep apnea specialist.

Wound care player Acelity lines up for what could be a $1B IPO

Private equity players took wound care company Kinetic Concepts private in a $5 billion buyout in 2011. Then these investors rolled in wound care peer Systagenix for $485 million in October 2013. Prior to that, KCI had already beefed itself up with the 2008 acquisition of tissue regeneration player LifeCell for $1.7 billion.

Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO

Rehovot, Israel-based Advanced Inhalation Therapies (AIT) has thrown its hat in the ring to raise up to $36.2 million in an IPO on the Nasdaq Exchange. That's despite the recent rocky market and a dearth of med tech IPOs of late.